• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Apecoin is Sinking

Apecoin (APE) is facing a decline, losing 3.3% to $1,347 this week. The altcoin experienced a more significant drop of 10.0% to $1,258 on Tuesday, but a subsequent strong recovery helped mitigate some of the losses. Apecoin, like many other altcoins, has been under ongoing pressure since the start of 2024. Additionally, the altcoin is dealing with its own negative news, as 15.6 million tokens (approximately $22 million) are set to be unblocked soon, leading to an increase in APE supply. The Bored Ape (BAYC) NFT collectibles are also reportedly underperforming.

From a technical perspective, the outlook for APE appears negative. The altcoin has moved below the uptrend and slipped beneath the support level at $1,500. This breach is considered a formal signal that prices might continue to decline, potentially reaching $1,000. However, this bearish scenario could be invalidated if prices manage to reclaim levels above $1,500 per token.

4213
Two Stocks to Skyrocket at the Start of 2024: NVIDIA

Shares of this artificial intelligence locomotive soared by 8.2% in the first two days of the week. The immediate focus was NVIDIA's leaked plan of launching its new chip, with an intention to distribute it in China. This would help to work legally surpassing the U.S .export restrictive rules. Mass production may start already in the Q2 2024r, two people familiar with the matter said. The launch was initially announced in November, but later it was delayed. New chip would be the most powerful of three China-focused items that the leader of this segment developed to comply with authorities. It has the potential to prevent squeezing market share in favour of Chinese domestic competitors. However, this was not the only good news from the company.

Nvidia also announced other components and software ahead of the Consumer Electronics Show in Las Vegas, including the GeForce RTX 40 SUPER series of graphics processors for video gamers. Besides, four Chinese electric vehicle brands, Li Auto, Great Wall Motor, Zeekr and Xiaomi confirmed they are ready to use Nvidia's DRIVE platform, which is the newest collection of technologies for autonomous driving and driver-assistance systems to perceive and respond to the environment. As an icing on the cake, JPMorgan shared the view that only NVIDIA's healthcare division has grown to a $1 billion+ business, listing computational demand for AI-related methods of drug discovery, genomics, patient diagnostics, as well as medical devices, wearables and robotics to add extra revenues. The latest price move has ensured a technical breakout well above the psychological resistance of $500 per share, as the next round figure of $600 becomes the new target for the near-term. Many analysts maintain Overweight ratings on NVIDIA stocks despite its market price more than tripled in 2023. Other companies boosted by the AI rally, including AMD, CrowdStrike, Qualcomm, Broadcom, Palo Alto Networks etc would also continue to benefit this winter from the industry trend led by NVIDIA.

4214
Two Stocks to Skyrocket at the Start of 2024: Merck

This January the oldest pharmaceutical and chemical concern in the world, which was founded in 1668 by Friedrich Jacob Merck, already updated its all-time highs at nearly $120 per share. Being one of the hits of 2022 due to its best selling Molnupiravir oral drug to inhibit the replication of coronavirus, the stock added about 10% to its market value since Christmas time.

Merck went all that way just in several days, supported by a purchase of cancer medicine developer Harpoon Therapeutics. The $680 million investment may substantially strengthen Merck's oncology portfolio with immunotherapies. Merck has made drastic efforts to guarantee future growth of its money streams after its blockbuster immunotherapy drug named Keytruda came close to losing key patents. Now the health segment bellwether got weapons to successfully confront biosimilar peers. Harpoon now has at least two immunotherapies in early stage of development for a type of lung cancer and for multiple myeloma. Immunotherapies are directing the patient's T cells to recognize and attack the cancer.

Merck's share price refused to fall after the dividend date on January 8, which was a good sign as well. It is scheduled to present its quarterly results on the first day of February and may continue to rise on expectations. The company set its new record in sales numbers at $16 billion in late October and may exceed this achievement. Its CEOs projected revenue growth of 5.3% YoY to earn $8.44 per share in 2024, compared to $7.66 in 2022, which was the best year in financial terms for Merck so far. The company sees its annual sales in 2023 within the range of $59.7 billion to $60.2 billion, which would be better than its initial projections of $58.6 billion to $59.6 billion.

Merck share price cleared the $100 epic technical resistance 15 months ago, and now it is aiming to conquer the next target area at $140-150. Increased sales of Molnupiravir in the winter season may contribute much to the ending quarter report after soaring by 47% in Q3, as the number of cases are growing once again, WHO said. Merck's anti-COVID drug was big in Japan, for example, while Merck doubled its annual forecast for the pill. Gardasil, which is proved to be an effective vaccine against cancers caused by the human papillomavirus, already provided sales of $2.59 billion in Q3 2023, up by 13% compared to the same period of 2022.

3552
B
Buying Airbus Stock as Boeing's Rival

Couple of days ago, I flew from Kuala Lumpur to Istanbul with an Airbus A350 on my way home. It was a wide-body twin-engine jet in a complete set. While being on board during long hours of flight, I just came across an article about the recent Boeing 737 Max 9 incident with a ripped plug in an emergency door to leave an unbelievable refrigerator-sized hole in the aircraft. Surely, it was rather disturbing news for me. Involuntary, my first instinct was to look around the cabin and there to verify with my eyes that no panels or other fuselage details were lost or missing. Yet, the next move of my mind was to understand that Airbus is the world's major rival of Boeing. If so, then Airbus stocks would get at least some advantage after U.S. regulators finally ordered the temporary grounding of around 171 Boeing jets on the weekend. More safety inspections would follow. Keeping in mind that Boeing faced heavy scrutiny over two fatal crashes of its 737 MAX planes in 2018 and 2019, which had long lasting consequences for its business, including share price damage, Boeing stock lost more than 8% of its market value on Monday. Therefore, I bought some shares of Airbus Group at €142.50 per share today after an intraday retreat from fresh highs that led prices to more or less acceptable levels, which are only two percentage points higher compared to last week's close. My opening price is 1.5% lower than morning peaks. Airbus holds an uptrend after gaining more than 25% in 2023, and further growth may even be accelerated after Boeing's loss. However, Boeing purchases from some nearest local lows are also part of my plans, as I believe that this famous American aircraft manufacturer would find a solution like providing some extra price discount for carriers to keep ordering its planes after a short pause. Eventually, technical faults will be corrected, the credibility gap situation is resolved. Again, the vast majority of the Boeing fleet does not have these plugs at all. The Max 9 model is the only one supporting a configuration that allows for that unfortunate plugged door option, as bigger planes are not manufactured in such a way. Even the 737 MAX 9 planes don't use it when carriers opt to install the maximum number of seats. Small carriers replace an additional emergency exit door with a plug only in case of less passenger seats option.

4238
219

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors